deltatrials
Terminated INTERVENTIONAL NCT05189366

Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy (SOPHNEURO)

Sponsor: Institut Cancerologie de l'Ouest

Conditions Glial Tumor
Updated 8 times since 2022 Last updated: Mar 25, 2026 Started: Oct 17, 2022 Primary completion: Nov 5, 2024 Completion: Nov 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment difficulties

Listed as NCT05189366, this observational or N/A phase trial focuses on Glial Tumor and remains terminated or withdrawn. Sponsored by Institut Cancerologie de l'Ouest, it has been updated 8 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshotNot Yet Recruiting~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshotRecruiting~Nov 2025 – ~Apr 2026 · 5 months · monthly snapshotTerminatedApr 16, 2026 – present · 2 months · daily API

Change History

8 versions recorded
  1. Apr 16, 2026 — Present [daily]

    Terminated

    Phase: NANone

  2. Nov 2025 — Apr 2026 [monthly]

    Terminated NA

    Status: RecruitingTerminated

  3. Sep 2024 — Nov 2025 [monthly]

    Recruiting NA

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting NA

  5. Sep 2023 — Jul 2024 [monthly]

    Recruiting NA

    Status: Not Yet RecruitingRecruiting

Show 3 earlier versions
  1. Sep 2022 — Sep 2023 [monthly]

    Not Yet Recruiting NA

  2. May 2022 — Sep 2022 [monthly]

    Not Yet Recruiting NA

  3. Feb 2022 — May 2022 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or neurocognitive disorders. In addition to these clinical symptoms, there is a high level of anxiety and depression in this population due to the severity of the diagnosis, with a major impact on the patients' quality of life. In this study, we are mainly interested in the proportion of this population with communication disorders where speech therapy is important In order to better take into account anxiety, which is often difficult to verbalise due to communication problems, sophrology can be proposed as an alternative to psychological support, which is often too complicated or inappropriate. After having noted positive feedback from patients after joint speech therapy and sophrology treatment, we wish to evaluate the interest of coupling sophrology treatment for patients with glial tumours requiring speech therapy. Our hypothesis is that this association would improve the level of anxiety, the quality of life and have a positive impact on the patient's speech therapy.

Contact Information

Sponsor contact:
  • Institut Cancerologie de l'Ouest
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations